Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023;30(4):502-505.
doi: 10.5603/CJ.a2023.0043. Epub 2023 Jul 4.

Andexanet alfa - Recommendations for clinical use. Multidisciplinary experts' standpoint

Jacek Kubica  1 , Piotr Adamski  2 , Robert Gajda  3 , Mariusz Gąsior  4 , Marek Gierlotka  5 , Robert Gil  6 , Miłosz Jaguszewski  7 , Aldona Kubica  8 , Wiktor Kuliczkowski  9 , Krzysztof Kurek  10 , Jerzy Robert Ładny  11 , Piotr Michalski  8 , Eliano Pio Navarese  2 , Piotr Niezgoda  2 , Małgorzata Ostrowska  2 , Agnieszka Tycińska  12
Affiliations

Andexanet alfa - Recommendations for clinical use. Multidisciplinary experts' standpoint

Jacek Kubica et al. Cardiol J. 2023.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Jacek Kubica: Fees for lectures and advisory board from AstraZeneca, Boehringer Ingelheim, Ferrer; Piotr Adamski: None declared; Robert Gajda: None declared; Mariusz Gąsior: Lectures fees from AstraZeneca, Berlin Chemie Menarini, Ferrer; Marek Gierlotka: Fees for lectures and advisory board from Amgen, Astra-Zeneca, Bayer, Berlin Chemie Menarini, Boehringer Ingelheim, Ferrer, Novartis, Sanofi Aventis; Robert Gil: Fees for lectures and advisory board from Amgen, AstraZeneca, Berlin Chemie Menarini, Boehringer Ingelheim, Ferrer, Gedeon Richter, Novartis, Sanofi Aventis, Sandoz; Miłosz Jaguszewski: Speaking fees and travel grants from Boheringer Ingelheim, Bayer, AstraZeneca, Pfizer; Aldona Kubica: Fees from AstraZeneca for lectures; Wiktor Kuliczkowski: None declared; Krzysztof Kurek: Fees for advisory board from AstraZeneca; Jerzy Robert Ładny: Fees for lectures and advisory board from AstraZeneca; Piotr Michalski: None declared; Eliano Pio Navarese: None declared; Piotr Niezgoda: None declared; Małgorzata Ostrowska: None declared; Agnieszka Tycińska: Lectures and consulting fees from AstraZeneca, Boehringer Ingelheim, Bayer, Ferrer, Novartis, Pfizer, Polpharma, Servier.

Similar articles

See all similar articles

Cited by

References

    1. Costa OS, Connolly SJ, Sharma M, et al. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Crit Care. 2022;26(1):180. doi: 10.1186/s13054-022-04043-8. - DOI - PMC - PubMed
    1. Miao B, Miller M, Lovelace B, et al. Burden-of-Illness associated with bleeding-related hospitalizations in atrial fibrillation patients: findings from the nationwide readmission database. TH Open. 2020;4(3):e211–e217. doi: 10.1055/s-0040-1716549. - DOI - PMC - PubMed
    1. Xian Y, Zhang S, Inohara T, et al. Clinical characteristics and outcomes associated with oral anticoagulant use among patients hospitalized with intracerebral hemorrhage. JAMA Netw Open. 2021;4(2):e2037438. doi: 10.1001/jamanetworkopen.2020.37438. - DOI - PMC - PubMed
    1. Heo YA. Andexanet Alfa: First Global Approval. Drugs. 2018;78(10):1049–1055. doi: 10.1007/s40265-018-0940-4. Erratum in: Drugs. 2018;78(12)1285. - DOI - PMC - PubMed
    1. Mehrotra S, Hoppensteadt D, Jeske W, et al. Differential neutralization of apixaban, betrixaban, edoxaban, and rivaroxaban by andexanet alfa as measured by whole blood thromboelastographic analysis. Clin Appl Thromb Hemost. 2022;28:10760296221138297. doi: 10.1177/10760296221138297. - DOI - PMC - PubMed